{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:27:11Z","timestamp":1794302831376,"version":"4.9.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajo.2026.08.039","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T14:25:12Z","timestamp":1788099912000},"page":"505-522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biomaterials in Retinal Surgery: Engineering the Future"],"prefix":"10.1016","volume":"292","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5515-7569","authenticated-orcid":false,"given":"ISMAIL AHMED","family":"DINDAR","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1830-3475","authenticated-orcid":false,"given":"MOLLY S.","family":"SHOICHET","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JONATHAN","family":"LABRIOLA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7410-3051","authenticated-orcid":false,"given":"ADAM","family":"FORMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROBERT","family":"DEVENYI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajo.2026.08.039_bib0001","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/aor.14824","article-title":"Pre-processing visual scenes for retinal prosthesis systems: a comprehensive review","volume":"48","author":"Holiel","year":"2024","journal-title":"Artif Organs"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.039_bib0002","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/nano11051221","article-title":"Biomaterials tailoring at the nanoscale for tissue engineering and advanced therapies","volume":"11","author":"Boffito","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ajo.2026.08.039_sbref0003","series-title":"World Report on Vision","year":"2019"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.039_bib0004","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/mi11050535","article-title":"Retinal prosthetic approaches to enhance visual perception for blind patients","volume":"11","author":"Shim","year":"2020","journal-title":"Micromachines"},{"key":"10.1016\/j.ajo.2026.08.039_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119633","article-title":"Biomolecules-derived biomaterials","volume":"230","author":"Datta","year":"2020","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.039_bib0006","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.ophtha.2016.06.049","article-title":"Five-year safety and performance results from the Argus II retinal prosthesis system clinical trial","volume":"123","author":"Da Cruz","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41551-021-00836-4","article-title":"Bioengineering strategies for restoring vision","volume":"7","author":"Cehajic-Kapetanovic","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"13","key":"10.1016\/j.ajo.2026.08.039_bib0008","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.3390\/s23135782","article-title":"Retinal prostheses: engineering and clinical perspectives for Vis restoration","volume":"23","author":"Wu","year":"2023","journal-title":"Sensors"},{"issue":"24","key":"10.1016\/j.ajo.2026.08.039_bib0009","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/S0042-6989(03)00457-7","article-title":"Visual perception in a blind subject with a chronic microelectronic retinal prosthesis","volume":"43","author":"Humayun","year":"2003","journal-title":"Vis Res"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.039_bib0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/2013.jamaophthalmol.221","article-title":"The detection of motion by blind subjects with the epiretinal 60-electrode (Argus II) retinal prosthesis","volume":"131","author":"Dorn","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2026.08.039_bib0011","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1167\/iovs.02-0817","article-title":"Perceptual efficacy of electrical stimulation of human retina with a microelectrode array during short-term surgical trials","volume":"44","author":"Rizzo","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.039_bib0012","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1109\/10.759051","article-title":"A computational model of electrical stimulation of the retinal ganglion cell","volume":"46","author":"Greenberg","year":"1999","journal-title":"IEEE Trans Biomed Eng"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0013","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1038\/s41467-025-58084-y","article-title":"Enhancing prosthetic vision by upgrade of a subretinal photovoltaic implant in situ","volume":"16","author":"Bhuckory","year":"2025","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0014","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa2501396","article-title":"Subretinal photovoltaic implant to restore vision in geographic atrophy due to AMD","volume":"394","author":"Holz","year":"2026","journal-title":"N Engl J Med"},{"issue":"1757","key":"10.1016\/j.ajo.2026.08.039_bib0015","article-title":"Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS","volume":"280","author":"Stingl","year":"2013","journal-title":"Proc R Soc B Biol Sci"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.039_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100510","article-title":"Prosthetic visual acuity with the PRIMA subretinal microchip in patients with atrophic age-related macular degeneration at 4 years follow-up","volume":"4","author":"Muqit","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100525","article-title":"A second-generation (44-channel) suprachoroidal retinal prosthesis: a single-arm clinical trial of feasibility","volume":"5","author":"Petoe","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.039_bib0018","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ceo.14502","article-title":"Second-generation (44-channel) suprachoroidal retinal prosthesis: surgical stability and safety during a 2-year clinical trial","volume":"53","author":"Allen","year":"2025","journal-title":"Clin Exp Ophthalmol"},{"issue":"24\u201325","key":"10.1016\/j.ajo.2026.08.039_bib0019","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.biomaterials.2008.04.047","article-title":"Conducting polymers for neural interfaces: challenges in developing an effective long-term implant","volume":"29","author":"Green","year":"2008","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0020","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1038\/ncomms6258","article-title":"Graphene-based carbon-layered electrode array technology for neural imaging and optogenetic applications","volume":"5","author":"Park","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajo.2026.08.039_bib0021","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3389\/fimmu.2019.01975","article-title":"Microglia in retinal degeneration","volume":"10","author":"Rashid","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajo.2026.08.039_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101356","article-title":"Animal models for the evaluation of retinal stem cell therapies","volume":"106","author":"Thomas","year":"2025","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0023","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.3390\/ijms24043342","article-title":"Vitreous substitutes from bench to the operating room in a translational approach: review and future endeavors in vitreoretinal surgery","volume":"24","author":"Confalonieri","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.039_bib0024","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.4103\/IJO.IJO_2417_23","article-title":"Vitreous substitutes and tamponades - a review of types, applications, and future directions","volume":"72","author":"Shettigar","year":"2024","journal-title":"Indian J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.survophthal.2010.09.001","article-title":"Vitreous substitutes: a comprehensive review","volume":"56","author":"Kleinberg","year":"2011","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0026","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ophtha.2018.11.014","article-title":"The pneumatic retinopexy versus vitrectomy for the management of primary rhegmatogenous retinal detachment outcomes randomized trial (PIVOT)","volume":"126","author":"Hillier","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.08.039_bib0027","first-page":"1","article-title":"Tamponade or filling effect: changes of forces in myopic eyes","volume":"2014","author":"Semeraro","year":"2014","journal-title":"Biomed Res Int"},{"issue":"7","key":"10.1016\/j.ajo.2026.08.039_bib0028","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0142-9612(99)00220-3","article-title":"Biomaterials used in the posterior segment of the eye","volume":"21","author":"Colthurst","year":"2000","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0029","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/ICU.0000000000000745","article-title":"Novel vitreous substitutes: the next frontier in vitreoretinal surgery","volume":"32","author":"Schulz","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0030","first-page":"437","article-title":"Vitreous substitutes: challenges and directions","volume":"8","author":"Gao","year":"2015","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0031","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/BF01977971","article-title":"\u00dcber die Behandlung der Netzhautabl\u00f6sung durch operative Entleerung der subretinalen Fl\u00fcssigkeit und Einspritzung von Luft in den Glask\u00f6rper","volume":"79","author":"Ohm","year":"1911","journal-title":"Albrecht von Graefes Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2026.08.039_bib0032","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.oret.2022.04.003","article-title":"Air versus sulfur hexafluoride gas tamponade for small and medium-sized macular holes","volume":"6","author":"Lindtj\u00f8rn","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.039_bib0033","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1097\/IAE.0b013e3181885009","article-title":"Outcomes of sulfur hexafluoride (SF6) versus perfluoropropane (C3F8) gas tamponade for macular hole surgery","volume":"28","author":"Kim","year":"2008","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0034","first-page":"11","article-title":"Step-wise approach to the management of submacular hemorrhage using pneumatic displacement and vitrectomy","volume":"42","author":"Chew","year":"2022","journal-title":"Manchester Protocol"},{"key":"10.1016\/j.ajo.2026.08.039_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/351804","article-title":"Vitreous substitutes: the present and the future","volume":"2014","author":"Donati","year":"2014","journal-title":"Biomed Res Int"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.039_bib0036","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/bjo.75.8.476","article-title":"Comparison of the effects of intraocular irrigating solutions on the corneal endothelium in intraocular lens implantation","volume":"75","author":"Matsuda","year":"1991","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0037","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archopht.1962.00960030394013","article-title":"Ocular tolerance to silicones: I. Replacement of aqueous and vitreous by silicone fluids","volume":"68","author":"Armaly","year":"1962","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0038","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/112067210001000301","article-title":"Semifluorinated alkanes: a new class of compounds with outstanding properties for use in ophthalmology","volume":"10","author":"Meinert","year":"2000","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.039_bib0039","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/IAE.0000000000003763","article-title":"Medium-term perfluoro-n-octane as rescue postoperative tamponade for very complex retinal detachments: anatomical and functional outcomes","volume":"43","author":"Shukla","year":"2023","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000488504","article-title":"Retinal toxicity of medical devices used during vitreoretinal surgery: a critical overview","volume":"240","author":"Januschowski","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ajo.2026.08.039_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/136031","article-title":"Heavy silicone oil as a long-term endotamponade agent for complicated retinal detachments","volume":"2014","author":"Prazeres","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0042","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/IAE.0b013e3181eef2fd","article-title":"Complications after heavy silicone oil tamponade in complicated retinal detachment","volume":"31","author":"Duan","year":"2011","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.039_bib0043","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/bjo.2004.055178","article-title":"A pilot study on the use of a perfluorohexyloctane\/silicone oil solution as a heavier than water internal tamponade agent","volume":"89","author":"Wong","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"10.1016\/j.ajo.2026.08.039_bib0044","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1163\/092050610X522729","article-title":"An injectable oxidated hyaluronic acid\/adipic acid dihydrazide hydrogel as a vitreous substitute","volume":"22","author":"Su","year":"2011","journal-title":"J Biomater Sci Polym Ed"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9394(14)74166-2","article-title":"Low viscosity liquid fluorochemicals in vitreous surgery","volume":"103","author":"Chang","year":"1987","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.039_bib0046","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/ac2714","article-title":"A highly transparent tri-polymer complex in situ hydrogel of HA, collagen and four-arm-PEG as potential vitreous substitute","volume":"16","author":"Yadav","year":"2021","journal-title":"Biomed Mater"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.039_bib0047","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10384-005-0255-3","article-title":"Application of thermo-setting gel as artificial vitreous","volume":"49","author":"Katagiri","year":"2005","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0048","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.actbio.2010.11.013","article-title":"Evaluation of viscoelastic poly(ethylene glycol) sols as vitreous substitutes in an experimental vitrectomy model in rabbits","volume":"7","author":"Pritchard","year":"2011","journal-title":"Acta Biomater"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.039_bib0049","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1016\/j.actbio.2012.09.026","article-title":"Evaluation of an in situ chemically crosslinked hydrogel as a long-term vitreous substitute material","volume":"9","author":"Tao","year":"2013","journal-title":"Acta Biomater"},{"issue":"18","key":"10.1016\/j.ajo.2026.08.039_bib0050","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1016\/j.polymer.2014.07.031","article-title":"Evaluation of a redox-initiated in situ hydrogel as vitreous substitute","volume":"55","author":"Chang","year":"2014","journal-title":"Polymer"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0051","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/2474126420946632","article-title":"PYK-1105: preclinical evaluation of a novel biodegradable vitreous substitute for retinal tamponade","volume":"5","author":"Stryjewski","year":"2021","journal-title":"J Vitreoretin Dis"},{"issue":"7\u20138","key":"10.1016\/j.ajo.2026.08.039_bib0052","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/02713680600813854","article-title":"Biocompatibility of polyvinylalcohol gel as a vitreous substitute","volume":"31","author":"Maruoka","year":"2006","journal-title":"Curr Eye Res"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.039_bib0053","first-page":"2491","article-title":"PVA\/STMP based hydrogels as potential substitutes of human vitreous","volume":"21","author":"Leone","year":"2010","journal-title":"J Mater Sci: Mater Med"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.039_bib0054","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41551-019-0382-7","article-title":"Retinal-detachment repair and vitreous-like-body reformation via a thermogelling polymer endotamponade","volume":"3","author":"Liu","year":"2019","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0055","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1039\/C9BM01603A","article-title":"A new highly transparent injectable PHA-based thermogelling vitreous substitute","volume":"8","author":"Xue","year":"2020","journal-title":"Biomater Sci"},{"issue":"12","key":"10.1016\/j.ajo.2026.08.039_bib0056","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1021\/acsabm.0c01266","article-title":"PCL-based thermogelling polymer: molecular weight effects on its suitability as vitreous tamponade","volume":"3","author":"Xue","year":"2020","journal-title":"ACS Appl Bio Mater"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.039_bib0057","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1163\/156856296X00453","article-title":"Poly(1-vinyl-2-pyrrolidinone) hydrogels as vitreous substitutes: histopathological evaluation in the animal eye","volume":"7","author":"Vijayasekaran","year":"1996","journal-title":"J Biomater Sci Polym Ed"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0058","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-4636(199604)30:4<441::AID-JBM2>3.0.CO;2-P","article-title":"Crosslinked poly (1-vinyl-2-pyrrolidinone) as a vitreous substitute","volume":"30","author":"Hong","year":"1996","journal-title":"J Biomed Mater Res"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0059","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/acsabm.8b00376","article-title":"Bioinspired fibrillary hydrogel with controlled swelling behavior: applicability as an artificial vitreous","volume":"2","author":"Santhanam","year":"2019","journal-title":"ACS Appl Bio Mater"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.039_bib0060","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/ma13061337","article-title":"Bioinspired thermosensitive hydrogel as a vitreous substitute: synthesis, properties, and progress of animal studies","volume":"13","author":"Laradji","year":"2020","journal-title":"Materials"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0061","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/pharmaceutics15030786","article-title":"Ex vivo visualization of distribution of intravitreal injections in the porcine vitreous and hydrogels simulating the vitreous","volume":"15","author":"Auel","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ajo.2026.08.039_bib0062","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.actbio.2016.07.051","article-title":"Biomimetic hydrogel with tunable mechanical properties for vitreous substitutes","volume":"43","author":"Santhanam","year":"2016","journal-title":"Acta Biomater"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.039_bib0063","first-page":"3085","article-title":"An in situ-forming polyzwitterion hydrogel: towards vitreous substitute application","volume":"6","author":"He","year":"2021","journal-title":"Bioact Mater"},{"issue":"11","key":"10.1016\/j.ajo.2026.08.039_bib0064","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201800711","article-title":"Antifouling super water absorbent supramolecular polymer hydrogel as an artificial vitreous body","volume":"5","author":"Wang","year":"2018","journal-title":"Adv Sci"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.039_bib0065","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00417-014-2714-3","article-title":"A new model for in vitro testing of vitreous substitute candidates","volume":"252","author":"Barth","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2026.08.039_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123842","article-title":"Meropenem loaded 4-arm-polyethylene-succinimidyl-carboxymethyl ester and hyaluronic acid based bacterial resistant hydrogel","volume":"235","author":"Yadav","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.ajo.2026.08.039_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.117519","article-title":"A self-healing and injectable hydrogel based on water-soluble chitosan and hyaluronic acid for vitreous substitute","volume":"256","author":"Wang","year":"2021","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.ajo.2026.08.039_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122459","article-title":"Injectable alginate-based in situ self-healable transparent hydrogel as a vitreous substitute with a tamponading function","volume":"305","author":"Choi","year":"2024","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.ajo.2026.08.039_bib0069","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1167\/tvst.9.13.34","article-title":"Alginate- and hyaluronic acid\u2013based hydrogels as vitreous substitutes: an in vitro evaluation","volume":"9","author":"Schulz","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.039_bib0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00006982-199004000-00012","article-title":"Evaluation of a viscoelastic solution of hydroxypropyl methylcellulose as a potential vitreous substitute","volume":"10","author":"Fernandez-Vigo","year":"1990","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2026.08.039_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119729","article-title":"Characterization of silk-hyaluronic acid composite hydrogels towards vitreous humor substitutes","volume":"233","author":"Raia","year":"2020","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.039_bib0072","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00417-017-3695-9","article-title":"Preliminary study of the safety and efficacy of medium-chain triglycerides for use as an intraocular tamponading agent in minipigs","volume":"255","author":"Soler","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.039_bib0073","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1167\/iovs.17-21536","article-title":"A self-assembling peptide gel as a vitreous substitute: a rabbit study","volume":"58","author":"Uesugi","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.039_bib0074","doi-asserted-by":"crossref","DOI":"10.1002\/admi.202101321","article-title":"DNA supramolecular hydrogel as a biocompatible artificial vitreous substitute","volume":"9","author":"Jin","year":"2022","journal-title":"Adv Mater Interfaces"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mabi.201100357","article-title":"Two-component in situ forming supramolecular hydrogels as advanced biomaterials in vitreous body surgery","volume":"12","author":"B\u00f6hm","year":"2012","journal-title":"Macromol Biosci"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.039_bib0076","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00417-011-1652-6","article-title":"Experimental vitreous tamponade using polyalkylimide hydrogel","volume":"249","author":"Crafoord","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2026.08.039_bib0077","unstructured":"Chang A. Retina 2019: I2\u2014Inspire Innovation, American Academy of Ophthalmology Retina Subspecialty Day. Vitreous substitutes following vitrectomy surgery. Proceedings of The Retina 2019."},{"key":"10.1016\/j.ajo.2026.08.039_bib0078","first-page":"327856","article-title":"Safety profile of long-term intraocular ophthalmic viscoelastic devices: a systematic review. 2026","author":"Khalil","year":"2025","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.039_bib0079","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1167\/iovs.11-7322","article-title":"The cross-linked biopolymer hyaluronic acid as an artificial vitreous substitute","volume":"53","author":"Schramm","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.039_bib0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/aos.15658","article-title":"Safety and performance assessment of hyaluronic acid-based vitreous substitutes in patients with phthisis bulbi","volume":"101","author":"Schulz","year":"2023","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0081","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172895","article-title":"Efficacy of two different thiol-modified crosslinked hyaluronate formulations as vitreous replacement compared to silicone oil in a model of retinal detachment","volume":"12","author":"Schnichels","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2026.08.039_bib0082","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.817353","article-title":"Long-term biocompatibility of a highly viscously thiol-modified cross-linked hyaluronate as a novel vitreous body substitute","volume":"13","author":"Hurst","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajo.2026.08.039_bib0083","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijbiomac.2022.03.046","article-title":"Injectable self-crosslinking hydrogels based on hyaluronic acid as vitreous substitutes","volume":"208","author":"Yu","year":"2022","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"10.1016\/j.ajo.2026.08.039_bib0084","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/jbm.a.36403","article-title":"The feasibility study of an in situ marine polysaccharide-based hydrogel as the vitreous substitute","volume":"106","author":"Jiang","year":"2018","journal-title":"J Biomed Mater Res A"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.039_bib0085","article-title":"Proteomic insight into the molecular function of the vitreous","volume":"10","author":"Skeie","year":"2015","journal-title":"Ed. PLoS One"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0086","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/IAE.0b013e3182618d2e","article-title":"Safety of medium-chain triglycerides used as an intraocular tamponading agent in an experimental vitrectomy model rabbit","volume":"33","author":"Auriol","year":"2013","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.ajo.2026.08.039_bib0087","first-page":"30","article-title":"New approaches to securing retinal breaks during surgery","volume":"26","author":"Stuart","year":"2022","journal-title":"EyeNet Magazine"},{"key":"10.1016\/j.ajo.2026.08.039_bib0088","unstructured":"Pykus Therapeutics, Inc. Pykus Therapeutics announces positive interim pilot clinical trial results of PYK-2101, a novel retinal sealant. 2025. Accessed April 1, 2026. https:\/\/www.prnewswire.com\/news-releases\/pykus-therapeutics-announces-positive-interim-pilot-clinical-trial-results-of-pyk-2101-a-novel-retinal-sealant-302445263.html"},{"key":"10.1016\/j.ajo.2026.08.039_bib0089","series-title":"Ophthalmic Biomaterials","first-page":"72","article-title":"Vitreous substitutes","volume":"Vol. 20","author":"Forman","year":"2025"},{"issue":"31","key":"10.1016\/j.ajo.2026.08.039_bib0090","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1039\/C9PY00862D","article-title":"Influence of ions to modulate hydrazone and oxime reaction kinetics to obtain dynamically cross-linked hyaluronic acid hydrogels","volume":"10","author":"Wang","year":"2019","journal-title":"Polym Chem"},{"key":"10.1016\/j.ajo.2026.08.039_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120750","article-title":"Stable oxime-crosslinked hyaluronan-based hydrogel as a biomimetic vitreous substitute","volume":"271","author":"Baker","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0092","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13287-024-04007-5","article-title":"Advances in retinal pigment epithelial cell transplantation for retinal degenerative diseases","volume":"15","author":"Liu","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0093","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/bioengineering12030278","article-title":"Advances in the study of age-related macular degeneration based on cell or cell-biomaterial scaffolds","volume":"12","author":"Li","year":"2025","journal-title":"Bioengineering"},{"issue":"11","key":"10.1016\/j.ajo.2026.08.039_bib0094","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.stem.2025.08.012","article-title":"Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: low-dose clinical outcomes","volume":"32","author":"Rao","year":"2025","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41536-025-00407-0","article-title":"Allogeneic RPE cell suspension manufactured at scale demonstrating preclinical safety and efficacy led to IND approval","volume":"10","author":"Soundararajan","year":"2025","journal-title":"NPJ Regen Med"},{"key":"10.1016\/j.ajo.2026.08.039_bib0096","unstructured":"Foundation Fighting Blindness. Summary of the ninth annual retinal cell & gene therapy innovation summit 2024. Accessed March 19, 2026. https:\/\/www.fightingblindness.org\/news\/innovation-summit-2024-summary-970"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0097","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13287-023-03282-y","article-title":"Stem cell sources and characterization in the development of cell-based products for treating retinal disease: an NEI town hall report","volume":"14","author":"Fortress","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ajo.2026.08.039_bib0098","unstructured":"National Eye Institute. A phase I\/IIa trial for autologous transplantation of induced pluripotent stem cell-derived retinal pigment epithelium for geographic atrophy associated with age-related macular degeneration. 2026. Accessed March 19, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04339764"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0099","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.4114","article-title":"Phase 1 clinical study of an embryonic stem cell\u2013derived retinal pigment epithelium patch in age-related macular degeneration","volume":"36","author":"Da Cruz","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajo.2026.08.039_bib0100","article-title":"A surgical kit for stem cell-derived retinal pigment epithelium transplants: collection, transportation, and subretinal delivery","volume":"10","author":"Li","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0101","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/stcltm\/szae004","article-title":"Recent progress in retinal pigment epithelium cell-based therapy for retinal disease","volume":"13","author":"Klymenko","year":"2024","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.039_bib0102","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/17425247.2014.927864","article-title":"Intravitreal drug delivery in retinal disease: are we out of our depth?","volume":"11","author":"Thakur","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.ajo.2026.08.039_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2024.103200","article-title":"Intravitreal therapeutic nanoparticles for age-related macular degeneration: design principles, progress and opportunities","volume":"329","author":"Zhang","year":"2024","journal-title":"Adv Colloid Interface Sci"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0104","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular drug delivery to the retina: current innovations and future perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.039_bib0105","first-page":"1038","article-title":"Nanotechnology in retinal drug delivery","volume":"11","author":"Jiang","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.08.039_bib0106","article-title":"Strategic lipid nanoparticle design dictates retinal delivery post inner limiting membrane disruption","author":"De Clerck","year":"2025","journal-title":"Drug Deliv and Transl Res"},{"issue":"32","key":"10.1016\/j.ajo.2026.08.039_bib0107","article-title":"Innovative nanotechnology in drug delivery systems for advanced treatment of posterior segment ocular diseases","volume":"11","author":"Wu","year":"2024","journal-title":"Adv Sci"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.039_bib0108","doi-asserted-by":"crossref","DOI":"10.1063\/5.0264382","article-title":"Recent Advancements in polymer science for retinal diseases: new frontiers in drug delivery systems","volume":"9","author":"Wang","year":"2025","journal-title":"APL Bioeng"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.039_bib0109","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/24741264241267065","article-title":"Extended intraocular drug-delivery platforms for the treatment of retinal and choroidal diseases","volume":"8","author":"Wykoff","year":"2024","journal-title":"J Vitreoretin Dis"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.039_bib0110","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s40123-025-01181-4","article-title":"Functional and anatomical outcomes of faricimab in previously treated wet age-related macular degeneration: systematic review and pooled analysis","volume":"14","author":"Khodor","year":"2025","journal-title":"Ophthalmol Ther"},{"issue":"10326","key":"10.1016\/j.ajo.2026.08.039_bib0111","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"10326","key":"10.1016\/j.ajo.2026.08.039_bib0112","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ajo.2026.08.039_bib0113","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1167\/iovs.12-9970","article-title":"Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases","volume":"53","author":"Kauper","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.039_bib0114","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400481","article-title":"Cell-based ciliary neurotrophic factor therapy for macular telangiectasia type 2","volume":"4","author":"Chew","year":"2025","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaophthalmol.2025.0001","article-title":"Port delivery system with ranibizumab vs monitoring in nonproliferative diabetic retinopathy without macular edema: the Pavilion randomized clinical trial","volume":"143","author":"Pieramici","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0116","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaophthalmol.2025.0006","article-title":"Continuous ranibizumab via port delivery system vs monthly ranibizumab for treatment of diabetic macular edema: the Pagoda randomized clinical trial","volume":"143","author":"Khanani","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.039_bib0117","article-title":"Dendrimer-triamcinolone acetonide reduces neuroinflammation, pathological angiogenesis, and neuroretinal dysfunction in ischemic retinopathy","volume":"4","author":"Cho","year":"2021","journal-title":"Adv Ther"},{"issue":"10432","key":"10.1016\/j.ajo.2026.08.039_bib0118","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"issue":"10432","key":"10.1016\/j.ajo.2026.08.039_bib0119","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2026.08.039_bib0120","unstructured":"Regeneron Pharmaceuticals, Inc. EYLEA HD (aflibercept) approved by FDA as first and only injectable anti-VEGF with dosing intervals up to 5 months for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). News release April 2, 2026. Accessed July 31, 2026. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/eylea-hdr-aflibercept-approved-fda-first-and-only-injectable\/"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.039_bib0121","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.oret.2024.05.021","article-title":"Interim results of the phase III Portal extension trial of the port delivery system with ranibizumab in neovascular age-related macular degeneration","volume":"9","author":"Campochiaro","year":"2025","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.039_bib0122","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2026.08.039_bib0123","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ophtha.2023.02.024","article-title":"Archway phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration 2-year results","volume":"130","author":"Regillo","year":"2023","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.039_bib0124","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.oret.2024.08.005","article-title":"Endophthalmitis in eyes treated with the port delivery system with ranibizumab","volume":"9","author":"Eichenbaum","year":"2025","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ophtha.2017.07.005","article-title":"Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration","volume":"125","author":"Daien","year":"2018","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0126","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4103\/1673-5374.205093","article-title":"Delivery of therapeutics to posterior eye segment: cell-encapsulating systems","volume":"12","author":"Wong","year":"2017","journal-title":"Neural Regen Res"},{"issue":"10411","key":"10.1016\/j.ajo.2026.08.039_bib0127","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2026.08.039_bib0128","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ajo.2025.04.016","article-title":"Pegcetacoplan treatment for geographic atrophy in age-related macular degeneration over 36 months: data from OAKS, DERBY, and GALE","volume":"276","author":"Wykoff","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"10411","key":"10.1016\/j.ajo.2026.08.039_bib0129","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ajo.2026.08.039_bib0130","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041278","article-title":"Overview of retinal gene therapy: current status and future challenges","volume":"13","author":"Bennett","year":"2023","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.039_bib0131","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/genes15060720","article-title":"Gene therapy for non-hereditary retinal disease: age-related macular degeneration, diabetic retinopathy, and beyond","volume":"15","author":"Rowe","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.ajo.2026.08.039_bib0132","article-title":"Gene therapies for inherited retinal diseases","author":"Kay","year":"2025","journal-title":"Retinal Physician. October"},{"key":"10.1016\/j.ajo.2026.08.039_bib0133","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ajo.2025.07.025","article-title":"Ocular delivery of viral vectors for retinal and choroidal vascular diseases: a review","volume":"279","author":"Agrawal","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"10436","key":"10.1016\/j.ajo.2026.08.039_bib0134","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101430","article-title":"Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 Vg\/eye and staggered dosing of fellow eyes","volume":"33","author":"Poulsen","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"10.1016\/j.ajo.2026.08.039_bib0136","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s40265-025-02237-2","article-title":"Can gene therapy transform the treatment landscape of posterior segment eye diseases? A comprehensive review of recent advancements","volume":"85","author":"Chen","year":"2025","journal-title":"Drugs"},{"issue":"10097","key":"10.1016\/j.ajo.2026.08.039_bib0137","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajo.2026.08.039_bib0138","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/biom14010122","article-title":"Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.ajo.2026.08.039_bib0139","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.64.7.39","article-title":"Gene therapy for retinal degenerative diseases: progress, challenges, and future directions","volume":"64","author":"Drag","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2026.08.039_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2026.03.014","article-title":"Laterally spreading AAV.SPR enables safe and efficient RS1 delivery to the macula after peripheral subretinal injection","author":"Andres-Mateos","year":"2026","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.ajo.2026.08.039_bib0141","article-title":"The gene therapy shift: a closer look at the science powering next-generation retinal treatments","volume":"5","author":"Regillo","year":"2025","journal-title":"Modern Retina"},{"issue":"21","key":"10.1016\/j.ajo.2026.08.039_bib0142","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290 -associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2026.08.039_bib0143","article-title":"FDA clears investigational new drug (IND) application for HG202 by HuidaGene therapeutics","author":"Crago","year":"2024","journal-title":"Modern Retina"},{"key":"10.1016\/j.ajo.2026.08.039_bib0144","unstructured":"HuidaGene Therapeutics Co., Ltd. Open-label dose-escalation study for CRISPR\/Cas13-RNA targeting therapy for the treatment of neovascular age-related macular degeneration in phase 1 trial (BRIGHT). ClinicalTrials.gov. 2024. Accessed March 21, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06623279."}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:01:55Z","timestamp":1794301315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426004952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":144,"alternative-id":["S0002939426004952"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.08.039","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomaterials in Retinal Surgery: Engineering the Future","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}